Sunmedical

Sun Pharma is India's largest pharmaceutical firm and among the world's top four specialty generic companies. It manufactures and markets over two thousand products globally across chronic and acute therapies. Its pipeline includes generics, branded generics, specialty drugs (including complex formulations), OTCs, antiretrovirals (ARVs), APIs, and intermediates. The company's clinical results span numerous approved products in neurology/psychiatry, cardiology, oncology, dermatology, gastroenterology and more.\n\nRecent highlights include DCGI approval for Molxvir® (molnupiravir) for COVID treatment in India and launch of Fexuclue® (fexuprazan) for erosive esophagitis.\n\nTheir R&D arm SPARC focuses on new chemical entities (NCEs) and novel drug delivery systems.\n\nThey have over forty manufacturing sites worldwide with billions of doses delivered annually.\n\nPipeline breadth cannot be precisely quantified due to product volume (>2000 marketed); see below for representative programs.